Dag Aarsland, MD, PhD, conducts research on a wide variety of topics within psychiatry and neuropsychiatry of older adults, with a focus on neuropsychiatric problems in people with Parkinson’s disease (PD) and Dementia with Lewy bodies. He has been actively involved in the international task forces developing diagnostic criteria for dementia and mild cognitive impairment in PD and Dementia with Lewy bodies. He played a central role in the study and subsequent paper that led to the licensing of rivastigmine for parkinsonian dementia. His current research centers on biomarker development. As the chair of the steering committee of The European-Dementia of Lewy Body Consortium, Professor Aarsland oversees groundbreaking initiatives. With more than 600 scientific papers, numerous books and extensive conference participation, his contributions significantly impact the fields of psychiatry and neurology.